Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
EP: 1.A High-Risk Myeloma Patient’s Path to CAR T: Personal and Clinical Perspectives
EP: 2.Behind the Scenes: Patient Education and Decision-Making for CAR T
EP: 3.Clinical Data Supporting CAR T in Earlier Lines: Updates From the CARTITUDE-1, CARTITUDE-4, and KarMMa-3 Trials
EP: 4.The Real-World Logistics of CAR T Therapy: Financial and Practical Considerations
EP: 5.From Collection to Infusion: Comprehensive CAR T Treatment and Management Strategies From CAR T Specialists
EP: 6.The Post–CAR T Journey: Long-Term Monitoring, Multidisciplinary Care, and Continuous Patient Support
EP: 7.Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Video content above is prompted by the following:
- How has your life changed since receiving CAR T therapy? How has CAR T therapy impacted your overall quality of life compared with your previous treatments? Based on your experience, what advice would you give to other patients with multiple myeloma who are considering CAR T therapy?
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
